A Study of Multiple Oral Doses of IX-01 in Healthy Male Subjects

Healthy Volunteers Clinical Trial

Official title:

A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Toleration, and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02792647
• Other study ID #: IX-0104
• Status: Completed
• Phase: Phase 1
• First received: June 2, 2016
• Last updated: November 9, 2016
• Start date: May 2016
• Est. completion date: October 2016

Study information

• Verified date: November 2016
• Source: Ixchelsis Limited
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine the PK of IX-01 and activity of CYP3A4.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: October 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Male healthy volunteer.

2. Aged 18-45 years at the time of signing the informed consent.

3. A body mass index (Quetelet index) in the range 18-30.

4. Total body weight >50 kg at screening.

5. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.

6. Willingness to comply with the contraception requirements of the trial.

7. Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate.

8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).

Exclusion Criteria:

1. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer, including any of the following findings:

• have lipid and/or liver function test results >1.25 x ULN or other clinical laboratory blood biochemistry test results outside the normal reference range unless discussed and approved by sponsor

• history of unexplained syncope

• family history of unexplained sudden death, or sudden death due to long QT syndrome

• QTcF interval >450 msec in 2 of 3 consecutive ECGs (additional ECGs may be recorded, if required, but a median QTcF = 450 msec from 3 consecutive ECGs is required for the volunteer to be considered eligible)

• bundle branch block and other conduction abnormalities, other than mild first degree atrio-ventricular block

• irregular rhythms other than sinus arrhythmia or occasional supraventricular ectopic beats

• T-wave configuration of insufficient quality for determination of QT interval, as assessed by the investigator

2. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.

3. Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory, haematological, renal or neurological function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness.

4. Surgery (e.g. stomach bypass) or medical condition that might affect absorption of medicines.

5. Presence or history of severe adverse reaction to any drug.

6. Use of any prescription or over-the-counter medicine during the 14 days before the first dose of trial medication, or intention to use any medicine during the trial, with the exception of short courses of medication considered by the investigator not to interfere with the safety of the subject or the integrity of the trial data (such as acetaminophen (paracetamol)).

7. Current use of any herbal remedy or nutritional supplement, or intention to use any such product during the study.

8. Participation in another clinical trial of a new chemical entity or a prescription medicine within the 3 months prior to the first dose.

9. Previous participation in this trial or any other clinical trial of an oxytocin receptor antagonist.

10. Presence or history of drug or alcohol abuse, or intake of more than 21 units of alcohol weekly or more than 5 cigarettes daily.

11. Blood pressure and heart rate in supine position at the screening examination outside the ranges 90-130 mm Hg systolic, 50-90 mm Hg diastolic; heart rate 50-90 beats/min, unless judged not clinically significant by an investigator.

12. Possibility that the volunteer will not cooperate with the requirements of the protocol.

13. Evidence of drug abuse on urine testing.

14. Positive test for hepatitis B, hepatitis C or HIV1 or HIV2.

15. Loss of more than 400 mL blood during the 3 months prior to the first dose, eg as a blood donor.

16. Objection by General Practitioner (GP) to volunteer entering trial.

17. Employee of the investigator site or any company involved in sponsoring, organising or conducting the trial, or immediate family of the employee. Immediate family is defined as spouse, parent, child or sibling, whether biologically related or legally adopted.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Placebo
Administered orally
• IX-01
Administered orally

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research	London

Sponsors (1)

Lead Sponsor	Collaborator
Ixchelsis Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with One or More Drug Related Adverse Events (AEs) or any Serious AEs		Baseline to Day 20 (Estimated up to 3 weeks)	Yes
Secondary	Peak Plasma Concentration (Cmax) of IX-01		Pre-dose to 24 hours post dose on Days 1 and 10	No
Secondary	Area Under the Plasma Concentration-Time Curve (AUCtau)		Pre-dose up to 24 hours post dose on Days 1 and 10	No
Secondary	Time of Peak Plasma Concentration (Tmax) of IX-01		Pre-dose to 24 hours post dose on Days 1 and 10	No
Secondary	Urine 6-ß-hydroxycortisol/cortisol Ratio		Pre-dose on Day 1 and Day 10	No
Secondary	Elimination Half Life (t1/2) of IX-01		Pre-dose up to 96 hours post dose on Day 10	No
Secondary	Accumulation Ratio (Racc) of IX-01 based on AUCtau		Pre-dose up to 24 hours post dose on Day 10	No
Secondary	Accumulation Ratio (Racc) of IX-01 based on Cmax		Pre-dose up to 24 hours post dose on Days 1 and 10	No
Secondary	Area Under the Concentration-Time Curve (AUCt) from Zero to the Time of Last Quantifiable Concentration (AUC(0-t)) of IX-01		Pre-dose to 96 hours post dose on Day 10	No
Secondary	Minimum Observed Concentration (Ctrough) of IX-01		Pre-dose on Days 2 to 10	No
Secondary	Elimination Rate Constant (Kel) of IX-01		Pre-dose up to 96 hours post dose on Day 10	No
Secondary	Apparent Clearance of IX-01		Pre-dose up to 24 hours post dose on Day 10	No
Secondary	Apparent Volume of Distribution During the Terminal Phase of IX-01		Pre-dose up to 96 hours post dose on Day 10	No